# EDGAR Filing Document

**Accession Number:** 0001390478
**File Stem:** 0001104659-26-075775
**Filing Date:** 2026-6
**Character Count:** 6848
**Document Hash:** cd6e1abbbbfcde56a898a052748f0d13
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-075775.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001104659-26-075775

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260616

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SELLAS Life Sciences Group, Inc.
- **CENTRAL INDEX KEY:** 0001390478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33958
- **FILM NUMBER:** 261103220

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** SUITE 2503
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 6462005278

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** SUITE 2503
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Galena Biopharma, Inc.
- **DATE OF NAME CHANGE:** 20110926

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RXi Pharmaceuticals Corp
- **DATE OF NAME CHANGE:** 20110926

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GALENA BIOPHARMA, INC.
- **DATE OF NAME CHANGE:** 20110922

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934** 

Date of report (Date of earliest event reported): **June 16, 2026**

**SELLAS Life Sciences Group, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-33958** | **20-8099512** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission <br> File Number) | (I.R.S. Employer <br> Identification No.) |
|  | **7 Times Square, Suite 2503<br> New York, NY 10036** |  |
|  | (Address of Principal Executive <br> Offices) (Zip Code) |  |
| Registrant's telephone number, including area code: **(646) 200-5278** | Registrant's telephone number, including area code: **(646) 200-5278** | Registrant's telephone number, including area code: **(646) 200-5278** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.0001 par value per share | SLS | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

*Annual Meeting of Stockholders*

On June 16, 2026, SELLAS Life Sciences Group, Inc. (the "Company") held its Annual Meeting of Stockholders ("Annual Meeting"). There were 115,511,771 shares of common stock, or approximately 62.59% of all outstanding shares, present in person or represented by proxy. At the Annual Meeting, the stockholders voted on the following five proposals and cast their votes as described below.

**Proposal 1**

The Company's stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.

---

| | | | |
|:---|:---|:---|:---|
| **NAME** | **FOR** | **WITHHELD** | **BROKER NON-VOTES** |
| Robert Van Nostrand | 66490143 | 4544035 | 44477593 |
| Jane Wasman | 65928448 | 5105730 | 44477593 |

---

**Proposal 2**

The Company's stockholders ratified the appointment of Baker Tilly US, LLP (as the successor to Moss Adams LLP) as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

---

| | | | |
|:---|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** | **BROKER NON-VOTES** |
| 112103701 | 2126460 | 1281610 |  |

---

**Proposal 3**

The Company's stockholders approved an amendment to the Company's 2023 Amended and Restated Equity Incentive Plan (the "2023 Equity Plan") to increase the number of shares of common stock available for sale under the 2023 Equity Plan by 20,000,000.

---

| | | | |
|:---|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** | **BROKER NON-VOTES** |
| 42906271 | 27310386 | 817521 | 44477593 |

---

**Proposal 4**

The Company's stockholders approved the non-binding, advisory resolution on the executive compensation of the Company's named executive officers.

---

| | | | |
|:---|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** | **BROKER NON-VOTES** |
| 52930792 | 15906732 | 2196654 | 44477593 |

---

**Proposal 5**

The Company's stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.

---

| | | | |
|:---|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** | **BROKER NON-VOTES** |
| 90571992 | 22200030 | 2739749 |  |

---

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | **SELLAS Life Sciences Group, Inc.** | **SELLAS Life Sciences Group, Inc.** | **SELLAS Life Sciences Group, Inc.** |
| Date: June 18, 2026 | By: | /s/ John T. Burns | /s/ John T. Burns |
|  |  | Name: | John T. Burns |
|  |  | Title: | Senior Vice President, Chief Financial Officer |

---